| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
1 Division of Epidemiology, Department of Health Research and Policy, 6 Department of Statistics, and 7 Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University, Stanford, California; 2 Instituto Nacional de Cancerologia, Mexico City, Mexico; 3 Instituto de Investigaciones Biomedicas, Universidad Nacional Autónoma de México, Mexico City, Mexico; 4 Infectious Diseases Pathology Activity, Centers for Disease Control and Prevention, Atlanta, Georgia; and 5 Division Poblacion y Salud, El Colegio de la Frontera Sur, San Cristobal de las Casas, Chiapas, Mexico
Helicobacter pylori causes gastric adenocarcinoma; whether treatment of H. pylori infection prevents this cancer remains unknown. In a randomized, double-blind, placebo-controlled trial of H. pylori eradication, we determined whether treatment for H. pylori decreases gastric cancer risk, using preneoplastic conditions as surrogate markers. A total of 248 healthy volunteers (age >40 years) randomly received H. pylori treatment (omeprazole, amoxicillin, clarythromycin; n = 122) or matched placebo (n = 126) for 1 week. Endoscopy was performed at baseline and at 6 weeks and 1 year. Seven biopsies from each endoscopy were reviewed by two pathologists using the revised Sydney classification. Outcome measures were both a consensus "worst biopsy" diagnosis and a weighted index score that incorporated degrees of severity of preneoplasia from all biopsies. We compared change in these outcomes over time between the two treatment groups. H. pylori cure rates for compliant subjects in the treatment arm were 79.2% and 75.7% at 6 weeks and 1 year, respectively. No statistically significant change in the worst biopsy diagnosis was observed from 6 weeks to 1 year between placebo and treated subjects (for improvement/worsening, placebo, 19.4%/10.5%; treatment, 22.5%/8.3%; P = 0.74). Change in index score was favorably greater in treatment compared with placebo subjects (intention-to-treat analysis, P = 0.03); this finding was particularly evident in the antrum. H. pylori eradication gave more favorable gastric histopathologies over 1 year than no treatment. Such incomplete regression suggests but does not prove that eradication of H. pylori decreases cancer risk.
This article has been cited by other articles:
|
|
 |
|
  C.-W. Lee, B. Rickman, A. B. Rogers, Z. Ge, T. C. Wang, and J. G. Fox Helicobacter pylori Eradication Prevents Progression of Gastric Cancer in Hypergastrinemic INS-GAS Mice Cancer Res., May 1, 2008; 68(9): 3540 - 3548. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P Malfertheiner, F Megraud, C O'Morain, F Bazzoli, E El-Omar, D Graham, R Hunt, T Rokkas, N Vakil, E J Kuipers, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report Gut, June 1, 2007; 56(6): 772 - 781. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. R. Taylor Prevention of Gastric Cancer: A Miss J Natl Cancer Inst, January 17, 2007; 99(2): 101 - 103. [Full Text] [PDF]
|
|
|
|
|
|
W.-c. You, L. M. Brown, L. Zhang, J.-y. Li, M.-l. Jin, Y.-s. Chang, J.-l. Ma, K.-f. Pan, W.-d. Liu, Y. Hu, et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J Natl Cancer Inst, July 19, 2006; 98(14): 974 - 983. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. Kusters, A. H. M. van Vliet, and E. J. Kuipers Pathogenesis of Helicobacter pylori Infection Clin. Microbiol. Rev., July 1, 2006; 19(3): 449 - 490. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Oh, H. Kling-Backhed, M. Giannakis, J. Xu, R. S. Fulton, L. A. Fulton, H. S. Cordum, C. Wang, G. Elliott, J. Edwards, et al. The complete genome sequence of a chronic atrophic gastritis Helicobacter pylori strain: Evolution during disease progression PNAS, June 27, 2006; 103(26): 9999 - 10004. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K Fall, W Ye, and O Nyren Antibiotic treatment and risk of gastric cancer Gut, June 1, 2006; 55(6): 793 - 796. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Tsai, R. Herrera-Goepfert, R. J. Tibshirani, S. Yang, A. Mohar, J. Guarner, and J. Parsonnet Changes of Gene Expression in Gastric Preneoplasia following Helicobacter pylori Eradication Therapy. Cancer Epidemiol. Biomarkers Prev., February 1, 2006; 15(2): 272 - 280. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R Mera, E T H Fontham, L E Bravo, J C Bravo, M B Piazuelo, M C Camargo, and P Correa Long term follow up of patients treated for Helicobacter pylori infection Gut, November 1, 2005; 54(11): 1536 - 1540. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. W. Stewart and A. S. Coates Cancer Prevention: A Global Perspective J. Clin. Oncol., January 10, 2005; 23(2): 392 - 403. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P Correa Is gastric cancer preventable? Gut, September 1, 2004; 53(9): 1217 - 1219. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |
